Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02 2024 - 4:05PM
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases, announced today that
Company management will participate in a fireside chat at the 23rd
Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at
12:45 p.m. ET / 9:45 a.m. PT.
A live webcast of the fireside chat can be accessed through the
Investors & Media section of the Company’s website at
http://investors.vaxcyte.com. A replay of the webcast will be
available for approximately 30 days following the conference.
About Vaxcyte Vaxcyte is a vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases. The Company is
developing broad-spectrum conjugate and novel protein vaccines to
prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum,
carrier-sparing pneumococcal conjugate vaccine (PCV) being
developed for the prevention of invasive pneumococcal disease
(IPD). VAX-31, the Company’s next-generation 31-valent PCV, is the
broadest-spectrum PCV candidate in the clinic today. Both VAX-24
and VAX-31 are designed to improve upon the standard-of-care PCVs
for both children and adults by covering the serotypes that are
responsible for a significant portion of IPD in circulation and are
associated with high case-fatality rates, antibiotic resistance and
meningitis, while maintaining coverage of previously circulating
strains that are currently contained through continued vaccination
practice.
Vaxcyte is re-engineering the way highly complex vaccines are
made through modern synthetic techniques, including advanced
chemistry and the XpressCF™ cell-free protein synthesis platform,
exclusively licensed from Sutro Biopharma, Inc. Unlike conventional
cell-based approaches, the Company’s system for producing
difficult-to-make proteins and antigens is intended to accelerate
its ability to efficiently create and deliver high-fidelity
vaccines with enhanced immunological benefits. Vaxcyte’s pipeline
also includes VAX-A1, a prophylactic vaccine candidate designed to
prevent Group A Strep infections; VAX-PG, a therapeutic vaccine
candidate designed to slow or stop the progression of periodontal
disease; and VAX-GI, a vaccine candidate designed to prevent
Shigella. Vaxcyte is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked.
For more information, visit www.vaxcyte.com.
Contacts:Jennifer Zibuda, Senior Director,
Investor RelationsVaxcyte,
Inc.860-729-8902investors@vaxcyte.com
Janet Graesser, Vice President, Corporate Communications and
Investor RelationsVaxcyte, Inc.917-685-8799media@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From Sep 2023 to Sep 2024